LCM
LGND icon

Legato Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Legato Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.92M Sell
15,569
-6,809
-30% -$1.6M 0.41% 43
2026
Q1 		$4.47M Sell
22,378
-3,863
-15% -$764K 0.41% 43
2025
Q4 		$4.96M Buy
26,241
+9,944
+61% +$1.91M 0.43% 35
2025
Q3 		$2.89M Buy
16,297
+4,695
+40% +$698K 0.31% 77
2025
Q2 		$1.32M Sell
11,602
-7,956
-41% -$850K 0.16% 209
2025
Q1 		$2.06M Buy
19,558
+1,500
+8% +$170K 0.28% 96
2024
Q4 		$1.93M Buy
18,058
+753
+4% +$85.1K 0.25% 111
2024
Q3 		$1.73M Buy
17,305
+3,185
+23% +$321K 0.21% 147
2024
Q2 		$1.19M Buy
14,120
+11,001
+353% +$875K 0.16% 212
2024
Q1 		$228K Buy
3,119
+144
+5% +$10.6K 0.03% 528
2023
Q4 		$212K Buy
+2,975
New +$176K 0.03% 522

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legato Capital Management's LGND Position: Q2 2026 in Review

Legato Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 30% in Q2 2026, selling an estimated $1.6M and leaving 15,569 shares worth $4.92M. The position accounts for 0.41% of the portfolio, ranked #43.

Legato Capital Management first reported a position in LGND in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.96M in Q4 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Legato Capital Management held 15,569 shares of Ligand Pharmaceuticals worth $4.92M as of Q2 2026.
  • Legato Capital Management sold 6,809 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.6M.
  • Ligand Pharmaceuticals made up 0.41% of Legato Capital Management's portfolio in Q2 2026, its #43 holding.
  • Legato Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Legato Capital Management's Ligand Pharmaceuticals position peaked at $4.96M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.